Bio-Techne (TECH) Stock Looks Fully Priced On Cash Flow And Earnings
Bio-Techne’s share price has risen over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the stock trading at a premium, which sits uneasily against a five year return where investors would have seen a sizeable decline.
- Over the past five years, Bio-Techne shareholders would have seen the stock fall around 39%, which puts the recent recovery into a longer term context of weak returns.
- Future growth in demand for Bio-Techne’s life sciences tools can support the current valuation. However, any setback in turning that demand into consistent cash flows may weigh heavily on what investors are willing to pay.
- Bio-Techne passes 0 of 6 valuation checks, which suggests it does not screen as a clear bargain on broader measures of value, including the full scorecard.
The issue now is whether Bio-Techne’s current share price already reflects an optimistic scenario, or if there is still room for upside relative to its intrinsic value estimate.
Is Bio-Techne Getting Expensive on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Bio-Techne should be worth today based on the cash it is expected to generate in the future. For Bio-Techne, the model starts from latest twelve month free cash flow of about $252.5 million and assumes that cash flows continue growing from current levels rather than resetting from a low base or declining.
On these projections, the DCF model points to an intrinsic value of about $53 per share, which sits well below the current market price. This implies the stock trades at roughly a 34.7% premium to its cash flow estimate. This gap suggests that at today’s price, investors are paying up for a more optimistic scenario than the cash flow model supports on its own.
On this cash flow view, Bio-Techne stock currently screens as overvalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Bio-Techne may be overvalued by 34.7%. Discover 49 high quality undervalued stocks or create your own screener to find better value opportunities.
Is Bio-Techne Getting Expensive on Earnings?
The P/E ratio is a useful way to gauge what you are paying for each dollar of Bio-Techne’s earnings. Right now, Bio-Techne trades on a P/E of about 101.9x, compared with an industry average of roughly 36.6x and a peer group average near 49.0x, so the stock is priced at a clear premium to both its sector and closer comparables.
The framework used here suggests a tailored fair P/E ratio of about 26.5x for Bio-Techne, which is far below the current level. Because this model penalises factors such as risk profile or the quality and visibility of earnings, the large gap is better read as a warning signal that the stock screens very expensively on earnings rather than as a precise target multiple.
On this earnings measure, Bio-Techne stock currently screens as overvalued relative to both peers and the modelled fair P/E range.
See what the numbers say about this price — find out in our valuation breakdown.
The Bio-Techne Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for Bio-Techne pick up where this valuation puzzle leaves off by spelling out which assumptions about Bio-Techne’s future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative sets out a fair value as a thesis about the business that you can revisit over time, and they sit on Simply Wall St’s Community page so you can see how that thesis evolves against new information.
Community views on Bio-Techne sit far apart, with one side seeing long-term product momentum and the other focused on funding and deal risk.
Bull case: roughly fairly valued
“With 80% of revenue from recurring consumables, including recent partnerships in high-value diagnostic biomarkers and a sharpened focus on portfolio diversification through targeted M&A, Bio-Techne is uniquely positioned to compound both revenue and free cash flow growth as healthcare and research spending expand with a rising global, aging population and increased demand for complex, personalized medicine solutions…”
Read the full Bull Case to see why Bio-Techne could be undervalued
Bear case: 30% overvalued
“Prolonged downturn in biotech funding, evidenced by a more than 40% year-over-year decline, is dampening innovation and procurement from smaller biotech customers, a significant end market for Bio-Techne, and this could constrain both top-line revenue growth and margin expansion if the trend continues…”
Read the full Bear Case to see why Bio-Techne could be overvalued
Do you think there’s more to the story for Bio-Techne? Head over to our Community to see what others are saying!
The Bottom Line
For Bio-Techne, both the Discounted Cash Flow (DCF) intrinsic value estimate and the current P/E-based market multiple point to the stock as overvalued, and broader valuation checks are also weak. That does not rule out strong future outcomes, but it does mean you are paying a full price today for that possibility. The crux of the bull versus bear debate is whether Bio-Techne can translate demand for its life sciences tools into durable, high quality cash flows that justify this premium, or whether expectations reset and the valuation comes back down to earth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Bio-Techne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
